<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01991860</url>
  </required_header>
  <id_info>
    <org_study_id>DP10015</org_study_id>
    <nct_id>NCT01991860</nct_id>
  </id_info>
  <brief_title>US Phase III Study of APD421 in PONV</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled Phase III Study of APD421 (Amisulpride for IV Injection) as Prophylaxis Against Post-operative Nausea and Vomiting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acacia Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acacia Pharma Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A comparison of the efficacy of APD421 and placebo in the prevention of PONV in patients at
      moderate-to-high risk of PONV.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Complete Response</measure>
    <time_frame>24 hours after the end of surgery</time_frame>
    <description>The primary efficacy analysis was a comparison of the incidence of Complete Response, defined as no emesis (vomiting or retching) and no use of rescue medication in the 24 hours after the end of surgery, between the active group and the placebo group using Pearson χ2 test with Yates's continuity correction, and with a two-sided significance level of 5%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With no Nausea.</measure>
    <time_frame>24 hours after end of surgery</time_frame>
    <description>Nausea (defined as the desire to vomit without the presence of expulsive muscular movements) measured on a 0-10 verbal response scale, where 0=no nausea at all and 10=the worst nausea imaginable. &quot;No nausea&quot; means no score ≥ 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With no Emesis</measure>
    <time_frame>24 hours after end of surgery</time_frame>
    <description>Emesis is defined as vomiting (production of even the smallest amount of stomach contents) or retching (muscular movements of vomiting but without expulsion of stomach contents, usually because of an empty stomach)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With no Use of Rescue Medication</measure>
    <time_frame>24 hours after end of surgery</time_frame>
    <description>Any agent given in the post-operative period with the intention of providing anti-emetic rescue was counted as rescue anti-emetic medication for the purposes of efficacy determination, even if it did not achieve control of emesis or was given incorrectly (e.g., wrong dosage or route). Any agent given in the post-operative period which would be expected, by virtue of its pharmacology, dosage and route, to exert a clinically meaningful anti-emetic effect was considered as rescue anti-emetic medication, even if administered inadvertently or without the intention of providing rescue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants With no Emesis, no Significant Nausea and no Use of Rescue Medication</measure>
    <time_frame>24 hours after the end of surgery</time_frame>
    <description>No occurrence of vomiting/retching, no nausea score ≥ 4 on verbal response scale (where 0=no nausea at all and 10=the worst nausea imaginable) and no use of rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants With no Significant Nausea</measure>
    <time_frame>24 hours after the end of surgery</time_frame>
    <description>Nausea (defined as the desire to vomit without the presence of expulsive muscular movements) measured on a 0-10 verbal response scale, where 0=no nausea at all and 10=the worst nausea imaginable. &quot;No significant nausea&quot; means no score ≥ 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With &quot;Total Response&quot;</measure>
    <time_frame>24 hours after the end of surgery</time_frame>
    <description>Total response is defined as no occurrence of vomiting/retching, no nausea score ≥ 1 and no use of rescue medication.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">364</enrollment>
  <condition>PONV</condition>
  <arm_group>
    <arm_group_label>APD421</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD421 (amisulpride), at 5mg given by single intravenous (IV) administration by slow push over one minute at induction of anaesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo given by single IV administration by slow push over one minute at induction of anaesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APD421- Amisulpride for IV injection</intervention_name>
    <description>APD421 ( Amisulpride) at 5mg given by single intravenous (IV) administration, by slow push over one minute, at induction of anaesthesia</description>
    <arm_group_label>APD421</arm_group_label>
    <other_name>Amisulpride for IV injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo given by single intravenous (IV) administration, by slow push over one minute, at induction of anaesthesia</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients ≥ 18 years of age

          -  Patients undergoing elective surgery (open or laparoscopic technique) under general
             anaesthesia, expected to last at least one hour from induction of anaesthesia to wound
             closure and expected to require at least one overnight stay in hospital

        Exclusion Criteria:

          -  Patients scheduled for outpatient/day case surgery

          -  Patients scheduled to undergo intra-thoracic, transplant or central nervous system
             surgery

          -  Patients scheduled to receive only a local anaesthetic/regional neuraxial (intrathecal
             or epidural) block

          -  Patients who are expected to remain ventilated for a period after surgery

          -  Patients who are expected to need a naso- or orogastric tube in situ after surgery is
             completed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tong J Gan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Medical College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 11, 2013</study_first_submitted>
  <study_first_submitted_qc>November 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <results_first_submitted>August 7, 2018</results_first_submitted>
  <results_first_submitted_qc>September 5, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 6, 2018</results_first_posted>
  <disposition_first_submitted>July 28, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>July 28, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 29, 2016</disposition_first_posted>
  <last_update_submitted>January 18, 2019</last_update_submitted>
  <last_update_submitted_qc>January 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amisulpride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of the 364 patients enrolled in the study (i.e. signed informed consent form), 22 patients were not randomised and not dosed. Of these, 4 withdrew their consent, 3 did not comply with the protocol procedures and 15 were not dosed for other unspecified reasons.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>5mg APD421</title>
          <description>A 5mg (2mL) dose of APD421 given by slow intravenous (IV) push over one minute at induction of anaesthesia</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>2mL of placebo given by slow intravenous (IV) push over one minute at induction of anaesthesia</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
                <participants group_id="P2" count="166"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="172"/>
                <participants group_id="P2" count="164"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 342 patients were randomised and dosed, comprising 176 randomised to APD421 and 166 to placebo. Of these, 4 patients from the APD421 group and 2 patients from the placebo group discontinued prematurely after randomisation</population>
      <group_list>
        <group group_id="B1">
          <title>5mg Dose APD421</title>
          <description>A 5mg dose of APD421 given by slow push, single intravenous (IV) administration over a time frame of one minute at induction of anaesthesia</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Single dose placebo given through intravenous (IV) administration</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="176"/>
            <count group_id="B2" value="166"/>
            <count group_id="B3" value="342"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.5" spread="14.2"/>
                    <measurement group_id="B2" value="53.0" spread="13.7"/>
                    <measurement group_id="B3" value="53.8" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="224"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="166"/>
                    <measurement group_id="B3" value="342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Complete Response</title>
        <description>The primary efficacy analysis was a comparison of the incidence of Complete Response, defined as no emesis (vomiting or retching) and no use of rescue medication in the 24 hours after the end of surgery, between the active group and the placebo group using Pearson χ2 test with Yates's continuity correction, and with a two-sided significance level of 5%.</description>
        <time_frame>24 hours after the end of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>APD421 at 5mg</title>
            <description>A 5mg (2mL) dose of APD421 given by slow intravenous (IV) push over one minute at induction of anaesthesia</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A 2mL dose of placebo given by slow intravenous (IV) push over one minute at induction of anaesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Response</title>
          <description>The primary efficacy analysis was a comparison of the incidence of Complete Response, defined as no emesis (vomiting or retching) and no use of rescue medication in the 24 hours after the end of surgery, between the active group and the placebo group using Pearson χ2 test with Yates's continuity correction, and with a two-sided significance level of 5%.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.033</p_value>
            <p_value_desc>2-sided</p_value_desc>
            <method>Chi-squared, Corrected</method>
            <method_desc>Yates’s continuity correction</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With no Nausea.</title>
        <description>Nausea (defined as the desire to vomit without the presence of expulsive muscular movements) measured on a 0-10 verbal response scale, where 0=no nausea at all and 10=the worst nausea imaginable. &quot;No nausea&quot; means no score ≥ 1.</description>
        <time_frame>24 hours after end of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>APD421 at 5mg</title>
            <description>A 5mg (2mL) dose of APD421 given by slow intravenous (IV) push over one minute at induction of anaesthesia</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A 2mL dose of placebo given by slow intravenous (IV) push over one minute at induction of anaesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With no Nausea.</title>
          <description>Nausea (defined as the desire to vomit without the presence of expulsive muscular movements) measured on a 0-10 verbal response scale, where 0=no nausea at all and 10=the worst nausea imaginable. &quot;No nausea&quot; means no score ≥ 1.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>Chi-squared, Corrected</method>
            <method_desc>Yates’s continuity correction</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With no Emesis</title>
        <description>Emesis is defined as vomiting (production of even the smallest amount of stomach contents) or retching (muscular movements of vomiting but without expulsion of stomach contents, usually because of an empty stomach)</description>
        <time_frame>24 hours after end of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>APD421 at 5mg</title>
            <description>A 5mg (2mL) dose of APD421 given by slow intravenous (IV) push over one minute at induction of anaesthesia</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A 2mL dose of placebo given by slow intravenous (IV) push over one minute at induction of anaesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With no Emesis</title>
          <description>Emesis is defined as vomiting (production of even the smallest amount of stomach contents) or retching (muscular movements of vomiting but without expulsion of stomach contents, usually because of an empty stomach)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                    <measurement group_id="O2" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.68</p_value>
            <method>Chi-squared, Corrected</method>
            <method_desc>Yates’s continuity correction</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With no Use of Rescue Medication</title>
        <description>Any agent given in the post-operative period with the intention of providing anti-emetic rescue was counted as rescue anti-emetic medication for the purposes of efficacy determination, even if it did not achieve control of emesis or was given incorrectly (e.g., wrong dosage or route). Any agent given in the post-operative period which would be expected, by virtue of its pharmacology, dosage and route, to exert a clinically meaningful anti-emetic effect was considered as rescue anti-emetic medication, even if administered inadvertently or without the intention of providing rescue.</description>
        <time_frame>24 hours after end of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>APD421 at 5mg</title>
            <description>A 5mg (2mL) dose of APD421 given by slow intravenous (IV) push over one minute at induction of anaesthesia</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A 2mL dose of placebo given by slow intravenous (IV) push over one minute at induction of anaesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With no Use of Rescue Medication</title>
          <description>Any agent given in the post-operative period with the intention of providing anti-emetic rescue was counted as rescue anti-emetic medication for the purposes of efficacy determination, even if it did not achieve control of emesis or was given incorrectly (e.g., wrong dosage or route). Any agent given in the post-operative period which would be expected, by virtue of its pharmacology, dosage and route, to exert a clinically meaningful anti-emetic effect was considered as rescue anti-emetic medication, even if administered inadvertently or without the intention of providing rescue.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.026</p_value>
            <method>Chi-squared, Corrected</method>
            <method_desc>Yates’s continuity correction</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants With no Emesis, no Significant Nausea and no Use of Rescue Medication</title>
        <description>No occurrence of vomiting/retching, no nausea score ≥ 4 on verbal response scale (where 0=no nausea at all and 10=the worst nausea imaginable) and no use of rescue medication.</description>
        <time_frame>24 hours after the end of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>APD421 at 5mg</title>
            <description>A 5mg (2mL) dose of APD421 given by slow intravenous (IV) push over one minute at induction of anaesthesia</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A 2mL dose of placebo given by slow intravenous (IV) push over one minute at induction of anaesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With no Emesis, no Significant Nausea and no Use of Rescue Medication</title>
          <description>No occurrence of vomiting/retching, no nausea score ≥ 4 on verbal response scale (where 0=no nausea at all and 10=the worst nausea imaginable) and no use of rescue medication.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.086</p_value>
            <method>Chi-squared, Corrected</method>
            <method_desc>Yates’s continuity correction</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants With no Significant Nausea</title>
        <description>Nausea (defined as the desire to vomit without the presence of expulsive muscular movements) measured on a 0-10 verbal response scale, where 0=no nausea at all and 10=the worst nausea imaginable. &quot;No significant nausea&quot; means no score ≥ 4.</description>
        <time_frame>24 hours after the end of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>APD421 at 5mg</title>
            <description>A 5mg (2mL) dose of APD421 given by slow intravenous (IV) push over one minute at induction of anaesthesia</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A 2mL dose of placebo given by slow intravenous (IV) push over one minute at induction of anaesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With no Significant Nausea</title>
          <description>Nausea (defined as the desire to vomit without the presence of expulsive muscular movements) measured on a 0-10 verbal response scale, where 0=no nausea at all and 10=the worst nausea imaginable. &quot;No significant nausea&quot; means no score ≥ 4.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.074</p_value>
            <method>Chi-squared, Corrected</method>
            <method_desc>Yates’s continuity correction</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With &quot;Total Response&quot;</title>
        <description>Total response is defined as no occurrence of vomiting/retching, no nausea score ≥ 1 and no use of rescue medication.</description>
        <time_frame>24 hours after the end of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>APD421 at 5mg</title>
            <description>A 5mg (2mL) dose of APD421 given by slow intravenous (IV) push over one minute at induction of anaesthesia</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A 2mL dose of placebo given by slow intravenous (IV) push over one minute at induction of anaesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With &quot;Total Response&quot;</title>
          <description>Total response is defined as no occurrence of vomiting/retching, no nausea score ≥ 1 and no use of rescue medication.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>Chi-squared, Corrected</method>
            <method_desc>Yates’s continuity correction</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>APD421 5mg Dose</title>
          <description>A 5mg dose of APD421 given by slow push, single intravenous (IV) administration over a time frame of one minute at induction of anaesthesia</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo given by single intravenous (IV) administration by slow push over one minute at induction of anaesthesia</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 16.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anaemia Postoperative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Post Procedural Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Post Operative Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.0</frequency_threshold>
        <default_vocab>MedDRA Version 16.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="169" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="160" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="176"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="176"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="176"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anaemia Postoperative</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="176"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" events="42" subjects_affected="42" subjects_at_risk="176"/>
                <counts group_id="E2" events="41" subjects_affected="41" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Bood Prolactin Increased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="176"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="33" subjects_affected="33" subjects_at_risk="176"/>
                <counts group_id="E2" events="38" subjects_affected="38" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="176"/>
                <counts group_id="E2" events="30" subjects_affected="30" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="176"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="176"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There were no limitations and caveats in this study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Gabriel Fox</name_or_title>
      <organization>Acacia Pharma Ltd</organization>
      <phone>44-(0)1223-919764</phone>
      <email>Gabrielfox@acaciapharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

